vs
BillionToOne, Inc.（BLLN）与CANTALOUPE, INC.（CTLP）财务数据对比。点击上方公司名可切换其他公司
BillionToOne, Inc.的季度营收约是CANTALOUPE, INC.的1.1倍（$83.5M vs $78.7M），BillionToOne, Inc.净利率更高（6.8% vs -0.1%，领先6.9%），BillionToOne, Inc.同比增速更快（117.4% vs 6.8%），BillionToOne, Inc.自由现金流更多（$6.5M vs $-614.0K）
BillionToOne, Inc.是一家生命科学与分子诊断企业，专注研发高精度基因检测解决方案，核心产品包括无创产前检测、肿瘤诊断试剂及罕见病筛查服务，服务全球多地的医疗机构、患者及科研合作方。
坎塔卢波（原美国技术公司）是一家美国科技企业，核心业务为ePort无现金支付受理技术，依托持专利的PCI合规ePort Connect服务开展运营。该服务可通过无线方式为消费者提供信用卡、借记卡以及Apple Pay、Google Pay等NFC钱包支付选项，同时为运营商提供遥测与机器间通信服务，ePort技术主要应用于...
BLLN vs CTLP — 直观对比
营收规模更大
BLLN
是对方的1.1倍
$78.7M
营收增速更快
BLLN
高出110.6%
6.8%
净利率更高
BLLN
高出6.9%
-0.1%
自由现金流更多
BLLN
多$7.1M
$-614.0K
损益表 — Q3 FY2025 vs Q2 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $83.5M | $78.7M |
| 净利润 | $5.7M | $-70.0K |
| 毛利率 | 69.9% | — |
| 营业利润率 | 11.5% | 2.0% |
| 净利率 | 6.8% | -0.1% |
| 营收同比 | 117.4% | 6.8% |
| 净利润同比 | 138.3% | -101.4% |
| 每股收益（稀释后） | $0.10 | $0.00 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BLLNCTLP
| Q4 25 | — | $78.7M | ||
| Q3 25 | $83.5M | $80.9M | ||
| Q2 25 | — | $82.6M | ||
| Q1 25 | — | $75.4M | ||
| Q4 24 | — | $73.7M | ||
| Q3 24 | $38.4M | $70.8M | ||
| Q2 24 | — | $72.7M | ||
| Q1 24 | — | $67.9M |
净利润BLLNCTLP
| Q4 25 | — | $-70.0K | ||
| Q3 25 | $5.7M | $-919.0K | ||
| Q2 25 | — | $6.8M | ||
| Q1 25 | — | $49.2M | ||
| Q4 24 | — | $5.0M | ||
| Q3 24 | $-14.9M | $3.6M | ||
| Q2 24 | — | $2.2M | ||
| Q1 24 | — | $4.7M |
毛利率BLLNCTLP
| Q4 25 | — | — | ||
| Q3 25 | 69.9% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 52.6% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 39.6% |
营业利润率BLLNCTLP
| Q4 25 | — | 2.0% | ||
| Q3 25 | 11.5% | 2.0% | ||
| Q2 25 | — | 6.3% | ||
| Q1 25 | — | 9.1% | ||
| Q4 24 | — | 8.4% | ||
| Q3 24 | -32.9% | 5.8% | ||
| Q2 24 | — | 4.9% | ||
| Q1 24 | — | 6.3% |
净利率BLLNCTLP
| Q4 25 | — | -0.1% | ||
| Q3 25 | 6.8% | -1.1% | ||
| Q2 25 | — | 8.3% | ||
| Q1 25 | — | 65.2% | ||
| Q4 24 | — | 6.7% | ||
| Q3 24 | -38.8% | 5.0% | ||
| Q2 24 | — | 3.0% | ||
| Q1 24 | — | 6.9% |
每股收益（稀释后）BLLNCTLP
| Q4 25 | — | $0.00 | ||
| Q3 25 | $0.10 | $-0.02 | ||
| Q2 25 | — | $0.10 | ||
| Q1 25 | — | $0.65 | ||
| Q4 24 | — | $0.07 | ||
| Q3 24 | $-1.47 | $0.04 | ||
| Q2 24 | — | $0.03 | ||
| Q1 24 | — | $0.06 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $195.2M | $53.0M |
| 总债务越低越好 | $55.0M | $37.7M |
| 股东权益账面价值 | $-239.5M | $252.5M |
| 总资产 | $327.5M | $381.9M |
| 负债/权益比越低杠杆越低 | — | 0.15× |
8季度趋势，按日历期对齐
现金及短期投资BLLNCTLP
| Q4 25 | — | $53.0M | ||
| Q3 25 | $195.2M | $55.0M | ||
| Q2 25 | — | $51.1M | ||
| Q1 25 | — | $46.3M | ||
| Q4 24 | — | $27.7M | ||
| Q3 24 | — | $33.1M | ||
| Q2 24 | — | $58.9M | ||
| Q1 24 | — | $50.2M |
总债务BLLNCTLP
| Q4 25 | — | $37.7M | ||
| Q3 25 | $55.0M | $38.3M | ||
| Q2 25 | — | $38.7M | ||
| Q1 25 | — | $39.2M | ||
| Q4 24 | — | $37.0M | ||
| Q3 24 | — | $37.3M | ||
| Q2 24 | — | $37.5M | ||
| Q1 24 | — | $38.1M |
股东权益BLLNCTLP
| Q4 25 | — | $252.5M | ||
| Q3 25 | $-239.5M | $251.8M | ||
| Q2 25 | — | $251.0M | ||
| Q1 25 | — | $240.7M | ||
| Q4 24 | — | $190.1M | ||
| Q3 24 | $-242.9M | $186.2M | ||
| Q2 24 | — | $181.7M | ||
| Q1 24 | — | $178.8M |
总资产BLLNCTLP
| Q4 25 | — | $381.9M | ||
| Q3 25 | $327.5M | $389.5M | ||
| Q2 25 | — | $381.9M | ||
| Q1 25 | — | $370.5M | ||
| Q4 24 | — | $303.0M | ||
| Q3 24 | — | $312.1M | ||
| Q2 24 | — | $335.6M | ||
| Q1 24 | — | $319.9M |
负债/权益比BLLNCTLP
| Q4 25 | — | 0.15× | ||
| Q3 25 | — | 0.15× | ||
| Q2 25 | — | 0.15× | ||
| Q1 25 | — | 0.16× | ||
| Q4 24 | — | 0.19× | ||
| Q3 24 | — | 0.20× | ||
| Q2 24 | — | 0.21× | ||
| Q1 24 | — | 0.21× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $13.8M | $3.1M |
| 自由现金流经营现金流 - 资本支出 | $6.5M | $-614.0K |
| 自由现金流率自由现金流/营收 | 7.7% | -0.8% |
| 资本支出强度资本支出/营收 | 8.8% | 4.8% |
| 现金转化率经营现金流/净利润 | 2.42× | — |
| 过去12个月自由现金流最近4个季度 | — | $25.8M |
8季度趋势，按日历期对齐
经营现金流BLLNCTLP
| Q4 25 | — | $3.1M | ||
| Q3 25 | $13.8M | $7.0M | ||
| Q2 25 | — | $9.4M | ||
| Q1 25 | — | $22.4M | ||
| Q4 24 | — | $522.0K | ||
| Q3 24 | — | $-12.0M | ||
| Q2 24 | — | $14.3M | ||
| Q1 24 | — | $14.7M |
自由现金流BLLNCTLP
| Q4 25 | — | $-614.0K | ||
| Q3 25 | $6.5M | $3.5M | ||
| Q2 25 | — | $4.3M | ||
| Q1 25 | — | $18.6M | ||
| Q4 24 | — | $-3.8M | ||
| Q3 24 | — | $-15.8M | ||
| Q2 24 | — | $8.5M | ||
| Q1 24 | — | $11.4M |
自由现金流率BLLNCTLP
| Q4 25 | — | -0.8% | ||
| Q3 25 | 7.7% | 4.4% | ||
| Q2 25 | — | 5.3% | ||
| Q1 25 | — | 24.6% | ||
| Q4 24 | — | -5.1% | ||
| Q3 24 | — | -22.3% | ||
| Q2 24 | — | 11.7% | ||
| Q1 24 | — | 16.9% |
资本支出强度BLLNCTLP
| Q4 25 | — | 4.8% | ||
| Q3 25 | 8.8% | 4.2% | ||
| Q2 25 | — | 6.2% | ||
| Q1 25 | — | 5.1% | ||
| Q4 24 | — | 5.8% | ||
| Q3 24 | — | 5.4% | ||
| Q2 24 | — | 7.9% | ||
| Q1 24 | — | 4.8% |
现金转化率BLLNCTLP
| Q4 25 | — | — | ||
| Q3 25 | 2.42× | — | ||
| Q2 25 | — | 1.38× | ||
| Q1 25 | — | 0.46× | ||
| Q4 24 | — | 0.10× | ||
| Q3 24 | — | -3.36× | ||
| Q2 24 | — | 6.47× | ||
| Q1 24 | — | 3.16× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BLLN
| Prenatal | $74.1M | 89% |
| Oncology | $8.7M | 10% |
CTLP
| Transaction Processing | $47.9M | 61% |
| Subscription Revenue | $21.8M | 28% |
| Products | $9.0M | 11% |
